List some reasons for performing a pneumonectomy or lobectomy
What are the chest radiograph is features in a pneumonectomy /Lobectomy?
On PA CXR the following features will be seen:
What is the importance of preoperative evaluation on pneumonectomy?
Preoperative evaluation is vital in both pneumonectomy and lobectomy because of the significant loss of lung function that follows.
Additionally, because such interventions are usually performed in patients with underlying lung disease, it is essential to assess the patients functional reserve and predicted pulmonary function follow surgery.
Pre-operative FEV1 over 2L is associated with low risk, no further testing required in absence of pulmonary hypertension (1.5L is acceptable for patients undergoing lobectomy)
Pre-operative FEV1 less than 2L is high risk, these patients require predicted post operative FEV1 and Gas transfer estimations following quantitative lung ventilation / perfusion scanning.
Preoperative cardiopulmonary tasting can also be performed. A Pre Operative VO2 Max less than 10mL/Kg/Min is associated with a high mortality risk (over 30%) versus those with preoperative VO2 Max over 15mL/Kg/min which are associated with a Mortality Risk less than 15%
Are you aware of any subtypes of pneumonectomy?
There are 2 main types of pneumonectomy:
The primary use of extrapleural pneumonectomy is in the treatment of malignant mesothelioma because this particular technique has been shown to have the best survival rates. (Clinical oncology study 2008)
If this patient had a lobectomy secondary to lung malignancy, can you suggest a likely subtype of lung cancer?
Surgery has a greater role in the management of ‘NSCLC’ rather than Small cell Carcinoma the latter of which has a poorer prognosis and is almost always unsuitable for surgical intervention by the time of presentation.
The most common type of NSCLC is squamous, followed by Adenocarcinoma, alveolar cell, large cell, carcinoid.
What proportion of NSCLC are suitable for surgery?
Approximately 25% of NSCLC will be suitable for surgical resection
Comment on the operative mortality or (i) Lobectomy and (ii) Pneumonectomy? Are there any differences between the right and left sides?
Operative mortality for lobectomy is approximately 2-4% and for pneumonectomy this rises to 6%.
There is a marked difference is mortality rates between the right and left sides following pneumonectomy. Right sided pneumonectomy is associated with higher overall mortality (10-12%) as compared to left-sided (1-3.5%). Reasons are uncertain for this difference but are most-likely due to life threatening complications that are encountered at a higher frequency following right-sided procedures such as post-pneumonectomy space empyema, pulmonary oedema, and bronchopleural fistula.
What is the ‘Post-Pneumonectomy syndrome’?
This syndrome results from the extrinsic compression of the distal trachea and main-stem bronchus due to mediastinal shifting and compensatory hyperinflation that occurs in the remaining lung.
Post-pneumonectomy syndrome occurs almost exclusively in patients with right sided pneumonectomy , approximately 6 months post surgery but can occurs years after the procedure.
The syndrome is characterised by progressive dyspnoea, cough, inspiratory stridor, and pneumonia. Treatment includes surgical repositioning of the mediastinum and filling fo the post-pneumonectomy space with non-absorbable material +/- stenting of the bronchi.
This condition can be fatal if not treated.
What are the indications for VATS procedure?
Lobectomy and pneumonectomy
Correction of spontaneous primary pneumothorax
Wedge resection
Lung parenchymal biopsy
Bullectomy and lung volume reductions surgery
What are the main differences in approach in VATS vs Open Thoracotomy?
VATS is associated with better cosmetic outcomes utilising smaller incisions, reduced in hospital recovery and total recovery. Less discomfort.
However it is associated with an increased risk of recurrent pneumothorax 5% vs 1% in Open thoracotomy.
Describe the Risk factors for developing Lung Cancer
Smoking - estimated 90% of all lung cancers caused by smoking. Adenocarcinoma is the only subtype not associated with smoking. Current smoker of 40 Pack years has a 20-fold increase risk.
Radiation therapy
Environmental exposure to passive smoke, asbestos, radon, metals (Arsenic, Chromium, Nickel)
Pulmonary fibrosis
COPD
Alpha 1 Antitrpsin deficiency,
Genetic factors i.e increased risk in those with family history.
Describe the histological classification of lung cancer.
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer
Name the common sites of Lung metastases.
Liver
Adrenal Glands
Bone - Osteolytic appearance, most commonly in vertebral bodies
Brain
What are the most common paraneoplastic syndromes that affect lung cancer patients?
Hypercalcaemia
SIADH
Describe the staging classification of NSCLC
Classified using TNM classification:
T1 tumour less than 3cm
T2 tumour greater than 3cm or involves main bronchus, or more than 2cm distal to the carina, or invading visceral pleura.
T3 tumour of any size that invades the chest wall, diaphragm, mediastinal pleura, parietal pericardium or tumour in main bronchus less than 2cm distal to the carina.
T4 tumour of any size that invades the mediastinum, heart, great vessels. Trachea, oesophagus. Or a tumour with malignant pleural/pericardial effusion or a tumour with satellite lung nodules within the same lobe as the primary.
N0 - No regional lymph nodes
N1 metastasis to ipsilateral peribronchial or hilar lymph nodes
N2 metastasis to ipsilateral mediastinal or subcarinal nodes
N3 metastasis to contralateral nodes or ipsilateral scalene or supracalvicular nodes.
M0 No distant Metastasis
M1 Distant metastases
Describe the classification of SCLC
Limited disease:
Extensive Disease:
What other prognostic factors help guide treatment in lung cancer?
WHO Performance Score:
Weight Los
Describe the management of patients with NSCLC
Patients should be discussed at a lung cancer MDT meeting and given information regarding their diagnosis and treatment. Lung cancer nurse specialists are essential to provide continuing support or the patient and coordinate their care.
Surgery:
Radical Radiotherapy:
-CHART (Continuous hyperfractionated accelerated radiotherapy) is considered in patients with Stage I, II, III disease who are inoperable but have good performance status
Chemotherapy:
Palliative Treatment:
Describe the management of small cell lung cancer
Combination treatment with radiotherapy and platinum-based chemotherapy
Prophylactic cranial irradiation considered in patients who respond to treatment - shown to reduce the incidence of brain metastases (Common after treatment for SCLC due to inadequate penetration of chemotherapy agents through the blood-brain barrier) and prolong survival
What treatment are available to help patients stop smoking?
Smoking cessation improves symptoms, improves lung function (there is a significantly reduced rate of decline in FEV1 with a return to near normal age-related decline over time) and is the only treatment sown to alter disease course.
Behavioural Treatment:
Nicotine Replacement Therapy:
Buproprion:
-Antidepressant which enhances CNS noradrenergic and dopaminergic function.
Varenicline:
-Partial agonist of nicotinic acetylcholine receptors, Side-effects include abnormal dreams, nausea and neuropsychiatric symptoms.
Some evidence of increased efficacy with combination treatment. No evidence for the effectiveness of acupuncture or hypnosis.
Describe the treatment options available for COPD
Non-Pharmacological Treatment:
Pharmcological Treatment:
Inhaled Corticosteroids:
Oral Corticosteroids:
-Associated with increased morbidity and mortality and therefore use of oral cortical steroids is not recommend. Trial of oral corticosteroids does not predict response to inhaled treatment.
Combination treatment LABA + ICS:
-TORCH Study showed salmteraol and fluticasone combined improved lung unction, health status and frequency exacerbation compared to individual therapies and placebo. Mortality reduced compared to placebo but had borderline significance. Further analysis has showed therapy to slow rate of lung function decline.
Theophylline:
Oxygen:
Non-Invasive Ventilation:
Describe the role of surgery in patients with COPD
Lung Volume reduction surgery:
Bullectomy:
Lung Transplant:
What causes an acute exacerbation of COPD?
Infection (60%):
Environmental pollution (10%)
Unknown Aetiology (30%)
How are infective exacerbations of COPD treated?